The last patient in Lundbeck’s phase 3 clinical trial, MASCOT, has been randomised ahead of schedule in a study evaluating amlenetug as a potential treatment for multiple system atrophy (MSA). The ...

Alterity Therapeutics has appointed internationally recognised expert in neurodegenerative diseases Daniel O Claassen as chief medical advisor. ... Read More The post Alterity bolsters clinical ...

Lundbeck announces last patient randomized ahead-of-schedule in phase 3 MASCOT clinical trial: Valby, Denmark Wednesday, March 11, 2026, 13:00 Hrs [IST] H. Lundbeck A/S (Lundbeck) ...

A study questioned the use of brain volume loss as a clinical trial endpoint in PPMS after finding a weak link to disability progression.

Professor Günter Höglinger, Lead Investigator of the Mascot trial, said: “Completing randomization of a global Phase 3 trial in MSA is a significant achievement for the field.” He added: “Advancing ...

The study ties first-trimester Oropouche infection to severe fetal neurodevelopmental anomalies and urges RT-PCR within 2-7 ...

Subtle drops in activity levels detected by wrist-worn sensors may predict worsening disability in MS patients, per a study.

Detailed price information for Voyager Therapeut (VYGR-Q) from The Globe and Mail including charting and trades.

Gaza: Patients and wounded in Gaza are facing increasingly harsh conditions after Israeli authorities again closed the Rafah land crossing, which had been partially reopened for a short period under a ...

Sport-related concussions are mild traumatic brain injuries that demand timely recognition and management. This review explores current evidence on pathophysiology, diagnosis, and treatment strategies ...

Gaza: Outgunned by the United States, Iran's rulers have been lashing out on multiple fronts -- but experts say what looks like a chaotic reaction is actually a time-tested strategy to outlast a ...

Eisai will present lecanemab data focused on real-world efficacy and safety, as well as four-year data from the Clarity AD Open-Label Extension trial. Eisai will also host one industry-sponsored ...